Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism IRAK1 antagonists(Interleukin-1 receptor-associated kinase 1 antagonists), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H16N4O3 |
InChIKeyJLLIANWHDQWCMY-UHFFFAOYSA-N |
CAS Registry848249-10-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | US | 01 Feb 2020 |